Lupin gains on receiving tentative approval for Generic Prezista tablets

Lupin Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 500257 | NSE: LUPIN

31 Dec 2014 Evaluate

Lupin is currently trading at Rs. 1439.00, up by 10.30 points or 0.72% from its previous closing of Rs. 1428.70 on the BSE.

The scrip opened at Rs. 1440.00 and has touched a high and low of Rs. 1442.00 and Rs. 1437.85 respectively. So far 2,442 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1500.00 on 24-Nov-2014 and a 52 week low of Rs. 855.00 on 30-Jan-2014.

Last one week high and low of the scrip stood at Rs. 1442.00 and Rs. 1392.00 respectively. The current market cap of the company is Rs. 64,664.00 crore.

The promoters holding in the company stood at 46.69% while Institutions and Non-Institutions held 42.71% and 10.60% respectively.

Pharma Major Lupin has received tentative approval for its Darunavir Ethanolate Tablets 75 mg, 150 mg, 300 mg, 400 mg, 600 mg and 800 mg from the United States Food and Drugs Administration (US FDA) to market a generic version of Janssen Products, LP (Janssen) Prezista Tablets 75 mg, 150 mg, 300 mg, 400 mg, 600 mg.

The company’s Darunavir Ethanolate Tablets 75 mg, 150 mg, 300 mg, 400 mg, 600 mg are the AB-rated generic equivalents of Janssen’s Prezista tablets and are indicated Lupin’s Darunavir Tablets is indicated for the treatment of HIV-1 infections. Prezista Tablets had annual U.S sales of $ 1.2 billion.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.